causal

Biotech Rose as Small-Molecule Pharma Declined

Two curves overlapped in pharma history: the exhaustion of low-hanging fruit in small-molecule chemistry and the growth of biotechnology built on recombinant DNA, which allowed bacteria to produce arbitrary proteins such as humanized insulin and monoclonal antibodies.

causalpending

Speaker

Alex

Evidence Quote

“the growth in what we can do with biotechnology tools like recombinant DNA and more recently, CRISPR”

Source

Alex Telford - Unlocking Innovation in Pharma - [Invest Like the Best, EP.360]— Invest Like the Best
Created: 11/14/2026, 6:42:06 AM

Your notes

Loading notes...